세계의 수의 순환기학 시장 : 동물 종류별, 제품별, 적응증별, 최종사용자별, 유통 채널별, 지역별, 기회 및 예측(2018-2032년)

Global veterinary cardiology market is projected to witness a CAGR of 7.21% during the forecast period 2025-2032, growing from USD 3.02 billion in 2024 to USD 5.27 billion in 2032. The global market for veterinary cardiology continues to grow, mainly fueled by rising pet ownership, increased awareness of animal heart health, and the growing demand for advanced diagnostic and treatment options. As companion animals live longer and pet owners become more invested in their pets' well-being, the need for specialized services such as cardiac imaging, monitoring, and therapeutic interventions is increasing.

Increases in technology, such as portable ECG devices, tele-cardiology and procedures that are less invasive in nature, are helping to increase the accessibility and accuracy of veterinary based cardiac care. Increases in veterinary infrastructure, pet insurance coverage and pet expenditures are also bolstering growth in the market further. The market environment is expected to remain strong going forward with North America having the largest market share and Asia-Pacific becoming the largest and fastest growing market as a result of increased pet adoption and improved veterinary care. The two biggest challenges facing the market are high equipment and operational costs, limited human resources pertaining to trained veterinary radiologists, and fragmented and inconsistent regulatory pathways in different regions. In addition, the continued incidence of heart conditions in dogs, specifically dilated cardiomyopathy and mitral valve disease, increases demand for cardiology services.

For instance, according to a September 2024 report from Tufts University, Cummings School of Veterinary Medicine, over 10% of animals examined by veterinarians show signs of cardiovascular disease. These conditions tend to worsen over time and are often difficult to detect in early stages, which highlights the increasing need for accurate diagnostic tools and long-term pharmaceutical treatment in the veterinary cardiology market.

Technological Advancement Driving Growth in the Veterinary Cardiology Market

Technological advancements are having a big impact on the expansion of the veterinary cardiology market. Recent advancements in veterinary cardiology includes the development of digital electrocardiograms (ECGs), high-resolution imaging systems, and portable ultrasound and diagnostic devices. These technological advancements have considerably improved the rate and accuracy of a cardiac assessment in the animal population. It has enabled veterinary professionals to diagnose chronic degenerative heart disease earlier and treat the heart condition quickly and accurately. Telemedicine is also contributing to this trend by providing remote access to veterinary cardiology specialists by regions that often can't provide access to channel veterinary cardiology services. The availability of user-friendly pet-specific medical devices is contributing to compliance and monitoring in treatment of pets with cardiac disease. As technology has continued to improve, it is making cardiac care more accessible, precise, efficient, and affordable and thus opening the door to greater demand worldwide and new skill sets for veterinary cardiology practices.

For instance, in September 2024, the Atlantic Veterinary College at the University of Prince Edward Island launched a clinical trial to treat cardiac tumors in dogs. The study explores the use of propranolol, a drug commonly used for similar conditions in children, marking a step forward in veterinary cardiac oncology. In another instance, in February 2025, Golden Hour launched STAT telemedicine Services for the veterinary industry. This service aims to improve access to real-time cardiology consultations, especially in areas with limited specialist availability.

Rising Pet Ownership Driving Adoption in Veterinary Cardiology Market

Rising levels of pet ownership in combination with the increasing humanization of companion animals will continue to affect the growth of the veterinary cardiology market. More households are adopting pets and seeing them as a family member. With this humanization of pets comes higher expectations around the veterinary care that pets receive, which has evolved into more advanced and specialized care, including cardiac diagnostics and treatment. This emotional bond is resulting in increased healthcare spending, as pet owners are becoming more proactive in seeking preventive care and paying attention to symptoms of heart-related diseases. The rise in pet adoption and pet owners, especially the younger generations has also expanded the total addressable market for pet services. Therefore, opportunities are consistently creating demand for cardiology solutions within veterinary practices, and driving clinics to invest in equipment, who perform cardiology, expertise, and innovative cardiovascular technologies to accommodate evolving pet parent consumer expectations.

For instance, data from the 2024 American Veterinary Medical Association (AVMA) Pet Ownership and Demographic Sourcebook revealed that 45.5% of United States households own dogs and 32.1% own cats, totaling approximately 89.7 million dogs and 73.8 million cats nationwide.

Pharmaceuticals Segment Dominates the Veterinary Cardiology Market

The pharmaceuticals segment plays a key role in the veterinary cardiology market. It includes drugs like pimobendan, spironolactone, and benazepril. These medicines help manage heart failure and other heart conditions in pets. They improve heart function and reduce symptoms. Most are easy to give and work well for long-term use. Pet owners are now more aware of early treatment options. This increases demand for heart medications. Clinics use these drugs regularly for cardiac care. New formulations, like oral solutions, are also being developed. These innovations support better dosing and compliance. As heart issues in pets rise, this segment will likely keep growing.

For instance, in April 2024, the U.S. Food and Drug Administration (FDA) approved the first generic version of pimobendan for managing congestive heart failure in dogs. This approval is expected to improve accessibility and reduce treatment costs, offering veterinarians and pet owners a more affordable option for long-term cardiac care.

North America Dominates the Market

North America maintains a leading position in the global veterinary cardiology market due to its advanced veterinary healthcare infrastructure, high standards of clinical practice, and strong demand for specialized services. The reason behind the dominance of this region is high percentage of pet ownership, increased awareness of cardiovascular diseases in their companion animals, and pet owners are generally more willing to invest in advanced veterinary care. North America has major corporate players, established diagnostic networks, and keen interest in innovative technologies advances impacting the field of veterinary cardiology, in particular imaging and ECG and telemedicine. Furthermore, robust regulatory policies, an ample supply of veterinary specialists, and ongoing investment in research and development are also unique characteristics of North America with both being positive indicators for continued veterinary cardiology growth and innovation. All of these factors synergistically contribute to North America being able to continue advancing the industry as well as continue to spur global trends and directions in veterinary cardiology.

For instance, in November 2024, Boehringer Ingelheim Vetmedica GmbH launched VETMEDIN Solution, the first FDA-approved oral solution for treating congestive heart failure in dogs. This new formulation allows for easier dosing and improved treatment compliance. Its introduction aligns with rising demand for advanced cardiac care in emerging veterinary markets.

Impact of U.S. Tariffs on Veterinary Cardiology Market

U.S. tariffs continue to affect the veterinary cardiology market. Import duties on medical devices and components drive up clinic expenses. Products like stethoscopes, monitors, and imaging systems are harder to afford. Clinics may reduce the frequency of cardiac screenings. Some avoid purchasing new equipment altogether. This slows down adoption of new technologies.

Clients may face higher fees for advanced diagnostics. Smaller practices feel the strain most. Their limited budgets make it harder to absorb rising costs. To adapt, many clinics seek cost-effective or refurbished devices. Others are renegotiating supplier contracts. Some turn to bulk purchasing or group buying networks. These steps help manage expenses without compromising care quality. However, the long-term impact may limit innovation and accessibility in veterinary cardiology across the globe.

Key Players Landscape and Outlook

Key players in the global veterinary cardiology market are focusing on innovation to stay competitive. IDEXX Laboratories, Inc.., Dextronix, Inc., and Antech Diagnostics, Inc. are incorporating artificial intelligence, cloud computing ECG systems, and wireless telemetry into their offerings. Bionet Co., Ltd. Contec Medical Systems Co., Ltd., and Shenzhen Comen Medical Instruments Co., Ltd. are working on portable and cost-effective cardiac monitors. These monitors are very useful for large-hospital settings and small clinics. Eickemeyer Veterinary Equipment Limited, Narang Medical Limited, iWorx Systems Inc., and New Gen Medical Systems Inc. are enhancing their products through ongoing research and development. Many of the firms are pursuing partnerships with veterinary clinics, universities, and other research institutions increase the discoveries they make and hopes of improving diagnostic accuracy or treatment outcomes. Innovation, accessibility, and reaching more countries are centered around tackling advancement in animal cardiac services to meet increasing requests for these services.

For instance, in June 2025, Boehringer Ingelheim Vetmedica GmbH and Eko Health Inc. partnered to improve heart murmur detection in dogs. The collaboration uses Eko's AI-enabled stethoscope technology to help vets detect cardiac issues earlier and more accurately during routine exams.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Cardiology Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Animal Type
    • 5.2.1.1. Companion Animals
    • 5.2.1.2. Livestock Animals
  • 5.2.2. By Product
    • 5.2.2.1. Pharmaceuticals
    • 5.2.2.2. Diagnostics
  • 5.2.3. By Indication
    • 5.2.3.1. Congestive Heart Failure
    • 5.2.3.2. Myocardial (Heart Muscle) Disease
    • 5.2.3.3. Arrhythmias
    • 5.2.3.4. Others
  • 5.2.4. By End-user
    • 5.2.4.1. Veterinary Hospitals and Clinics
    • 5.2.4.2. Academic and Research Institutions
    • 5.2.4.3. Others
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacy
    • 5.2.5.2. Retail Pharmacy
    • 5.2.5.3. E-Commerce
  • 5.2.6. By Region
    • 5.2.6.1. North America
    • 5.2.6.2. Europe
    • 5.2.6.3. Asia-Pacific
    • 5.2.6.4. South America
    • 5.2.6.5. Middle East and Africa
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Animal Type
  • 5.3.2. By Product
  • 5.3.3. By Indication
  • 5.3.4. By End-user
  • 5.3.5. By Distribution Channel
  • 5.3.6. By Region

6. North America Veterinary Cardiology Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Animal Type
    • 6.2.1.1. Companion Animals
    • 6.2.1.2. Livestock Animals
  • 6.2.2. By Product
    • 6.2.2.1. Pharmaceuticals
    • 6.2.2.2. Diagnostics
  • 6.2.3. By Indication
    • 6.2.3.1. Congestive Heart Failure
    • 6.2.3.2. Myocardial (Heart Muscle) Disease
    • 6.2.3.3. Arrhythmias
    • 6.2.3.4. Others
  • 6.2.4. By End-user
    • 6.2.4.1. Veterinary Hospitals and Clinics
    • 6.2.4.2. Academic and Research Institutions
    • 6.2.4.3. Others
  • 6.2.5. By Distribution Channel
    • 6.2.5.1. Hospital Pharmacy
    • 6.2.5.2. Retail Pharmacy
    • 6.2.5.3. E-Commerce
  • 6.2.6. By Country Share
    • 6.2.6.1. United States
    • 6.2.6.2. Canada
    • 6.2.6.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Veterinary Cardiology Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.1.1. Companion Animals
        • 6.3.1.2.1.2. Livestock Animals
      • 6.3.1.2.2. By Product
        • 6.3.1.2.2.1. Pharmaceuticals
        • 6.3.1.2.2.2. Diagnostics
      • 6.3.1.2.3. By Indication
        • 6.3.1.2.3.1. Congestive Heart Failure
        • 6.3.1.2.3.2. Myocardial (Heart Muscle) Disease
        • 6.3.1.2.3.3. Arrhythmias
        • 6.3.1.2.3.4. Others
      • 6.3.1.2.4. By End-user
        • 6.3.1.2.4.1. Veterinary Hospitals and Clinics
        • 6.3.1.2.4.2. Academic and Research Institutions
        • 6.3.1.2.4.3. Others
      • 6.3.1.2.5. By Distribution Channel
        • 6.3.1.2.5.1. Hospital Pharmacy
        • 6.3.1.2.5.2. Retail Pharmacy
        • 6.3.1.2.5.3. E-Commerce
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Cardiology Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Veterinary Cardiology Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Veterinary Cardiology Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Veterinary Cardiology Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Clinical Trial Landscape

18. Regulatory Framework and Innovation

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Dextronix, Inc
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. IDEXX Laboratories, Inc.
  • 20.3.3. Contec Medical Systems Co. Ltd
  • 20.3.4. Antech Diagnostics, Inc.
  • 20.3.5. Bionet Co., Ltd
  • 20.3.6. Eickemeyer Veterinary Equipment Limited
  • 20.3.7. Narang Medical Limited
  • 20.3.8. Shenzhen Comen Medical Instruments Co., Ltd
  • 20.3.9. iWorx Systems Inc
  • 20.3.10. New Gen Medical Systems Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer